PUBBLICAZIONI SCIENTIFICHE

I risultati delle ricerche finanziate dalla Associazione in questi anni sono stati presentati

in numerosi convegni e congressi nazionali ed internazionali e pubblicati su importanti riviste scientifiche.

56 – Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era

Abstract: The most common breast cancer (BC) susceptibility genes beyond BRCA1/2 are ATM and CHEK2. For the purpose of exploring the clinicopathologic characteristics of
Abstract: The importance of molecular re-characterization of metastatic disease with the purpose of monitoring tumor evolution has been acknowledged in numerous clinical guidelines for
Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R-HCVAD regimen [rituximab plus HyperCVAD
Purpose The FOLL05 trial compared R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) and R-FM (rituximab
The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC)
Objective: To evaluate the effectiveness of transvaginal ultrasound (TVU) and serum CA-125 measurement in women at different risk of developing ovarian cancer/fallopian tube cancer
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different
Non-Hodgkin lymphomas encompass a heterogeneous group of cancers, with 85–90% arising from B lymphocytes and the remainder deriving from T lymphocytes or NK lymphocytes.
Recently, in an attempt to improve the discrimination power of the international prognostic index (IPI), patients with diffuse large B-cell lymphoma were evaluated to
Although new treatments have been widely studied to improve the survival of patients with metastatic breast cancer (BC), prognosis continues to be poor with
Purpose Combined-modality treatment is standard treatment for patients with clinical stage I/II Hodgkin lymphoma (HL). We hypothesized that an early positron emission tomography (PET)
Background: [ 18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients and methods: In
Background: Risk-reducing mastectomy (RRM) decreases breast cancer (BC) risk in BRCA1/2 mutation carriers by up to 95%, but the Italian attitude towards this procedure
Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by
In patients with myelodysplastic syndromes (MDS), the likelihood of having a sustained response to azacitidine is increased by maximizing treatment duration. This is important
Whether high-dose therapy (HDT) plus autologous stem cell transplantation (ASCT) ought to be included in the initial treatment plan for those patients with unfavourable
The results presented here demonstrate that a cisdiamminedichloroplatinum(II) (DDP)-resistant human ovarian-carcinoma cell line isalso cross-resistant to the spermine analogue N1 ,N12-bis(ethyl)spermine (BESPM). W e

RICERCA SUL CANCRO

PUBBLICAZIONI SCIENTIFICHE

Tutti i nostri articoli pubblicati sulle riviste scientifiche
VAI

PROGETTI DI RICERCA

I progetti di ricerca che abbiamo sostenuto
VAI

BORSE DI STUDIO E STAGE ALL'ESTERO

Borse di studio e stage all'estero per ricercatori finanziati dall'Associazione
VAI

PREMI DI STUDIO

Stage all'estero per ricercatori sostenuti dall'Associazione
VAI

PREMIO "PIER CAMILLO BECCARIA"

Conferito ogni anno ad un illustre studioso che si è distinto nella lotta contro i tumori
VAI